This study will consist of 2 parts. In Part 1, the participants will be randomized to switch from stable antiretroviral (ARV) therapy to either E/C/F/TAF or F/R/TAF. The participants maintaining HIV-1 RNA < 50 copies/mL and tolerating E/C/F/TAF or F/R/TAF through Part 1 will continue to Part 2 where they will receive the LDV/SOF treatment.